Table 2.
H. pylori cure rates by vacA
| Authors | Year | Country |
vacA Diagnosis |
Regimen, duration (d) |
vacAtype | Cure rate (n) | P value |
|---|---|---|---|---|---|---|---|
| Lopez-Brea et al. | 1999 | Spain | PCR | BAM** | s1 vs. s2 | 50% (3/6) vs. 80% (21/26) | >0.05 |
| van Doorn et al. | 2000 | Netherlands | PCR | LBTM, 4 or 5 | s1 vs. s2 | 75% (56/75) vs. 50% (11/22) | 0.03* |
| Rudi et al. | 2002 | Germany | PCR | PPI+AC or CM, 7 | s1 vs. s2 | 87% (80/92) vs. 83% (19/23) | 0.59 |
| Scholte et al. | 2002 | Netherland | PCR | OAC, 7 | s1 vs. s2 | 100% (11/11) vs. 85% (11/13) | 0.17 |
| Chaudhuri et al. | 2003 | India | PCR | OAC, 10 | s1 vs. s2 | 62% (26/42) vs. 40% (2/5) | >0.05 |
| Russo et al. | 2003 | Italy | PCR | LAC, 7 | s1 vs. s2 | 77% (67/87) vs. 43% (9/21) | <0.01* |
| De Francesco et al. | 2004 | Italy | PCR | RA+RCT or RAC, 10 |
s1 vs. s2 | 91% (40/44) vs. 90% (46/51) | >0.05 |
| Zhao et al. | 2007 | China | PCR | EAC** | s1 vs. s2 | 93% (53/57) vs. 44% (4/9) | <0.05* |
| Rudi et al. | 2002 | Germany | PCR | PPI+AC or CM,7 | m1 vs. m2 | 90% (44/49) vs. 83% (55/66) | 0.32 |
| Scholte et al. | 2002 | Netherland | PCR | OAC,7 | m1 vs. m2 | 100% (5/5) vs. 83% (16/19) | 0.34 |
| Chaudhuri et al. | 2003 | India | PCR | OAC, 10 | m1 vs. m2 | 46% (11/24) vs. 74% (17/23) | <0.05* |
| De Francesco et al. | 2004 | Italy | PCR | RA+RCT or RAC, 10 |
m1 vs. m2 | 89% (33/37) vs. 90% (52/58) | >0.05 |
| Zhao et al. | 2007 | China | PCR | EAC** | m1 vs. m2 | 94% (17/18) vs. 83% (40/48) | <0.05* |
| Total | s1 vs. s2 | 81% (336/414) vs. 72% (123/170) |
0.02* | ||||
| m1 vs. m2 | 83% (110/133) vs. 84% (180/214) |
0.73 | |||||
Data are based on per-protocol (PP) analyses.
Significantly different
Eradication duration were not shown
P >0.05: No detailed data were available; the author described the results as not significant.
A, amoxicillin; R, rabeprazole; AC, amoxicillin and clarithromycin; ACM, bismuth, clarithromycin, and metronidazole; BAM, bismuth, amoxicillin, and metronidazole; CM, clarithromycin and metronidazole; CT, clarithromycin and tinidazole; EAC, esomeprazole, amoxicillin, and clarithromycin; LAC, lansoprazole, amoxicillin, and clarithromycin; LBTM, lansoprazole, bismuth, tetracycline, and metronidazole; OA, omeprazole and amoxicillin; OAC, omeprazole, amoxicillin, and clarithromycin; OC, omeprazole and clarithromycin; PAC, pantoprazole, amoxicillin, and clarithromycin; PAM, pantoprazole, amoxicillin, and metronidazole; PFC, pantoprazole, furazolidone, and clarithromycin; PPI, proton pump inhibitor; RA, rabeprazole and amoxicillin; RAC, rabeprazole, amoxicillin, and clarithromycin; RCT, rabeprazole, clarithromycin, and tinidazole